Nuala Moran
FeatureTransparency measures forced on pharma
Previous misdemeanours are compelling the pharmaceutical industry to be more open with financial information and clinical data, writes Nuala Moran
FeatureThe hunt for innovation
Big pharma companies are embracing a more open and collaborative approach. Nuala Moran discovers who’s working with whom
NewsThreat to Israeli participation in EU science programme
Rule change means that EU funding cannot go to institutions in occupied territories amid warnings all scientific cooperation could cease
FeaturePhasing out fire retardants
With many brominated flame retardants facing bans, Nuala Moran examines the industry’s dash for new ones
FeatureChanging the rules of extraction
As the price of oil goes up, reserves previously uneconomical to exploit become attractive. Nuala Moran explores the chemical technology being used
- Business
Single EU patent agreed for 2014
European commission says long awaited single patent will cut cost of filing by 87%
BusinessCan the UK fund CCS?
EU is offering €1.5 billion in funding but lack of co-ordination with UK scheme threatens participation
BusinessLow salt diet to flush out oil
Better understanding of oil–clay chemistry could increase the world’s recoverable oil by billions of barrels
NewsPlan to tackle EU funding disparity
Pilot project will use infrastructure cash to create ‘pockets of excellence’ in eastern Europe
NewsEurope-wide single patent stalls again
Row over ultimate control of the planned European single patent court brings the process to a juddering halt once more
- News
Campaigners win fight to reform English libel laws
New bill will protect scientists and journalists from vexatious suits when highlighting concerns with scientific evidence
- News
World's first therapeutic cancer vaccine approved
US biotech Antigenics wins Russian approval to market kidney cancer treatment
- Feature
The chemistry of private equity
Private equity has transformed the chemicals industry, but can it play the same role in high-risk R&D driven companies? Nuala Moran reports